Correlation Found Between ChemoFx(R) Assay and Improved OS in Patients with Ovarian Cancer
May 21, 2008
Precision Therapeutics announced that the ChemoFx(R) Assay, a cell-based test that examines the response of a specific patient's tumor to various chemotherapies, correlates with significantly longer overall survival (OS) in patients with primary ovarian cancer. Patients who received a treatment determined by ChemoFx to lead to the best tumor response had an overall survival 1.4 times longer than those receiving a treatment shown by ChemoFx to be non-responsive. Sean McDonald, CEO of PTI, said "The goal of ChemoFx is to empower patients and physicians with additional diagnostic information to help determine the most appropriate course of therapy for each individual patient." This retrospective, multi-center analysis is a published abstract at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago and is available on the here.
« BodyMedia Releases New SenseWear WMS Armband | | TOA Named to Visionaries Quandrant in 2008 Field Service Management Magic Quandrant »
